CPMC submitted comments to CMS urging reform of the Medicare “14-Day Rule,” which delays access to timely molecular testing for cancer patients. The group recommended allowing labs to bill based on the date of test performance, simplifying billing guidance, and aligning policy with modern cancer care. These comments were developed with the expertise of Dr. Bruce Quinn, a recognized Medicare diagnostics policy expert.